• Signed and dated informed consent form.

• Male or female, \> 18 years old.

• Minimum body weight of 50 kilograms (kg).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

• Histologically or cytologically confirmed locally advanced or metastatic NSCLC or locally advanced or metastatic solid tumor with bone metastasis

• Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC), and are not a candidate for further standard anti-neoplastic therapy and/or have exhibited intolerance to and/or declined clinically applicable salvage therapies, and/or have declined therapy.

• Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.

• At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging. Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease

• All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.

• Adequate hematopoietic, hepatic and renal function

• Agree to adequate contraception for up to 120 days after the last dose of study drug.

• Negative serum pregnancy test for women of childbearing potential

• All primary and metastatic disease sites are amenable to LDRT

• For solid tumors with bone metastases subjects (Part 2 Cohort B): receiving zoledronic acid for solid tumors with bone metastases